Artios Pharma, Ian Smith
Artios Pharma has appointed Ian Smith as chief medical officer overseeing the company’s preclinical and clinical development strategy, regulatory, and medical activities.
The company focuses on DNA damage response (DDR) and is currently developing a pipeline of oncology treatments.
Smith will join Artios from Eli Lilly, where he previously served as a senior medical director. Prior to his work at Eli Lilly, Smith worked at AstraZeneca for eight years advancing early clinical development for oncology compounds. Smith also was responsible for the development of lead oncology drugs within the Global Medicines Development Division at AZ.
Niall Martin, CEO at Artios, commented on Smith’s appointment saying, “[He] brings a wealth of experience in advancing oncology compounds from early to late-stage clinical development and through to market. With his expertise and the guidance we will receive from our newly formed Clinical Advisory Board, Artios is in a strong position to accelerate the development of its pipeline of highly promising first-in-class DDR therapies.”